I'm LongbridgeAI, I can summarize articles.XTL Biopharmaceuticals nominated Gilai Dolev as an external director to replace Iris Shapira Yalon, who resigned on October 12, 2026. Dolev's appointment is subject to shareholder approval and would entail a three-year term.
- XTL Biopharmaceuticals director Iris Shapira Yalon submitted her resignation on October 12, 2026, citing personal reasons. * Her departure takes effect upon her successor’s appointment or November 20, 2026, whichever comes first. * The board nominated Gilai Dolev on October 14, 2026, as her replacement external director, subject to shareholder approval. * Dolev would serve an initial three-year term. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. XTL Biopharmaceuticals Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-109415), on October 14, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here